Back to Newsroom

Arrowhead Pharmaceuticals Presents New Data on ARC-F12 and ARC-LPA Using DPCsqTM Subcutaneous RNAi Delivery Vehicle

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today delivered oral presentations on ARC-LPA, its preclinical development program targeting lipoprotein (a), for the treatment of cardiovascular disease, and ARC-F12, its preclinical development program targeting factor XII (F12) for the prophylactic treatment of thromboembolism and hereditary angioedema, at the American Heart Association’s Scientific Sessions 2016 in New Orleans. These data show advancements being made in the ARC-LPA and ARC-F12 programs and in the development of Arrowhead’s proprietary DPCsqTM delivery vehicle designed for subcutaneous administration of RNAi therapeutics.

Click here to read the full release